MX2017016823A - Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados. - Google Patents
Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados.Info
- Publication number
- MX2017016823A MX2017016823A MX2017016823A MX2017016823A MX2017016823A MX 2017016823 A MX2017016823 A MX 2017016823A MX 2017016823 A MX2017016823 A MX 2017016823A MX 2017016823 A MX2017016823 A MX 2017016823A MX 2017016823 A MX2017016823 A MX 2017016823A
- Authority
- MX
- Mexico
- Prior art keywords
- oral dosage
- hydroxyprogesterone
- pharmaceutically acceptable
- ester
- related methods
- Prior art date
Links
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- -1 17-hydroxyprogesterone ester Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 abstract 5
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 abstract 4
- 150000002148 esters Chemical class 0.000 abstract 4
- 239000003937 drug carrier Substances 0.000 abstract 2
- 230000035935 pregnancy Effects 0.000 abstract 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000008367 deionised water Substances 0.000 abstract 1
- 229910021641 deionized water Inorganic materials 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona formas de dosificación oral biodisponibles que contienen ésteres de 17- hidroxiprogesterona, así como métodos relacionados. Las formas de dosificación orales pueden formularse para soporte de embarazo y pueden incluir una cantidad terapéuticamente efectiva de un éster de 17-hidroxiprogesterona y un portador farmacéuticamente aceptable. En otra modalidad, se proporciona una forma de dosificación oral farmacéuticamente aceptable para el soporte de embarazo. La dosificación oral farmacéuticamente aceptable puede incluir una cantidad terapéuticamente efectiva de un éster de 17- hidroxiprogesterona y un portador farmacéuticamente aceptable. La forma de dosificación oral puede, cuando se mide utilizando un aparato de disolución de tipo II de USP en 900 ml de agua desionizada con 0.5 g/l (p/v) de lauril sulfato de sodio a 50 RPM a 37°C, liberar al menos el 20% en peso de la dosis del éster de 17-hidroxiprogesterona después de 60 minutos, o en la liberación alternativa al menos un 20% en peso o más después de 60 minutos que una forma de dosificación oral dosificada de forma equivalente sin el portador.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562183031P | 2015-06-22 | 2015-06-22 | |
| US201662295951P | 2016-02-16 | 2016-02-16 | |
| PCT/US2016/038822 WO2016210003A2 (en) | 2015-06-22 | 2016-06-22 | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017016823A true MX2017016823A (es) | 2018-03-12 |
Family
ID=57586205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016823A MX2017016823A (es) | 2015-06-22 | 2016-06-22 | Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20170035781A1 (es) |
| EP (1) | EP3310359B1 (es) |
| JP (1) | JP2018522854A (es) |
| CN (1) | CN107847506A (es) |
| AU (1) | AU2016284459B2 (es) |
| BR (1) | BR112017027688A2 (es) |
| ES (1) | ES3005883T3 (es) |
| IL (1) | IL256493A (es) |
| MX (1) | MX2017016823A (es) |
| PH (1) | PH12017502416A1 (es) |
| WO (1) | WO2016210003A2 (es) |
| ZA (1) | ZA201801692B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109219442A (zh) | 2016-04-04 | 2019-01-15 | Omeza有限公司 | 鱼油局部组合物 |
| PE20211285A1 (es) * | 2018-11-27 | 2021-07-19 | Bayer Ag | Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios |
| CN109662953B (zh) * | 2019-02-18 | 2022-05-10 | 威海金思力生物科技股份有限公司 | 一种维生素d软胶囊及其制作方法 |
| WO2021081276A1 (en) * | 2019-10-23 | 2021-04-29 | Slayback Pharma Llc | Stable pharmaceutical compositions containing estradiol and progesterone for oral administration |
| CN111135153B (zh) * | 2020-01-21 | 2025-08-19 | 安士制药（中山）有限公司 | 一种熊去氧胆酸胶囊及其制备方法 |
| CN113616660A (zh) * | 2020-05-07 | 2021-11-09 | 深圳埃格林医药有限公司 | 孕激素制剂及其用途 |
| US12502396B2 (en) * | 2020-10-27 | 2025-12-23 | Lipocine Inc. | Hydroxyprogesterone caproate compositions and methods of use in preventing preterm birth |
| US11370811B1 (en) | 2020-11-20 | 2022-06-28 | Lipocine Inc. | (17-)-3-oxoandrost-4-en-17-yl dodecanoate compositions and methods of preparation and use |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| IT202100013898A1 (it) * | 2021-05-27 | 2022-11-27 | Hulka S R L | Composizione comprendente un estere di alfa-tocoferolo per la riduzione del rischio di parto pretermine |
| CN116077416B (zh) * | 2021-11-05 | 2024-12-06 | 深圳埃格林医药有限公司 | 一种包含孕激素的口服制剂及制备方法和应用 |
| WO2024023173A1 (en) * | 2022-07-27 | 2024-02-01 | Ipsico Ug | Solid pharmaceutical dosage form comprising a bcs class ii drug and a method for producing the same |
| US12186327B2 (en) | 2022-08-29 | 2025-01-07 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| US12589135B2 (en) * | 2023-08-21 | 2026-03-31 | Cmpd Licensing, Llc | Topical administration of GLP-1 receptor agonists |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3164520A (en) | 1962-10-29 | 1965-01-05 | Olin Mathieson | Injectable steroid compositions containing at least 75% benzyl benzoate |
| NL151903B (nl) | 1965-03-24 | 1977-01-17 | Schering Ag | Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat. |
| FR2408345A1 (fr) | 1976-11-30 | 1979-06-08 | Besins Jean Louis | Nouvelle composition a action anti-conceptionnelle |
| US4230702A (en) | 1978-01-09 | 1980-10-28 | Kali-Chemie Pharma Gmbh | Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents |
| US4439432A (en) | 1982-03-22 | 1984-03-27 | Peat Raymond F | Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols |
| US5314882A (en) | 1984-01-03 | 1994-05-24 | International Foundation For Biochemical Endocrinology | Method for promoting growth and improved meat quality in meat producing animals with female steroidal hormones |
| US5140021A (en) | 1986-04-16 | 1992-08-18 | Genesis Systems Corporation | Method and dosage form for treatment of premenstrual syndrome |
| GB8730011D0 (en) | 1987-12-23 | 1988-02-03 | Smithkline Dauelsberg | Pharmaceutical compositions |
| AU5157590A (en) | 1989-02-06 | 1990-08-24 | Abbott Laboratories | Pharmaceutical compositions for oral administration |
| IT1252867B (it) | 1991-12-31 | 1995-06-28 | Gentili Ist Spa | Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita' |
| DK95093D0 (da) | 1993-08-20 | 1993-08-20 | Novo Nordisk As | Farmaceutisk formulering indeholdende et hormon |
| US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5633011A (en) * | 1994-08-04 | 1997-05-27 | Alza Corporation | Progesterone replacement therapy |
| EP0777491B1 (de) | 1994-08-23 | 2004-11-17 | Deutsche Gelatine-Fabriken Stoess AG | Verwendung von geschmacksneutralem, hydrolysiertem kollagen und mittel enthaltend dasselbe |
| DE19718012C1 (de) | 1997-04-29 | 1998-10-08 | Jenapharm Gmbh | Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe |
| DE19739916C2 (de) | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
| FR2772617B1 (fr) | 1997-12-19 | 2001-03-09 | Besins Iscovesco Lab | Comprime de progesterone et son procede de preparation |
| FR2775599B1 (fr) | 1998-03-09 | 2001-08-17 | Besins Iscovesco Lab | Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation |
| US6602521B1 (en) | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
| US6214815B1 (en) | 1998-12-23 | 2001-04-10 | Ortho-Mcneil Pharmaceuticals, Inc. | Triphasic oral contraceptive |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| GB9907715D0 (en) | 1999-04-01 | 1999-05-26 | Scherer Corp R P | Pharmaceutical compositions |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| US20020131988A1 (en) | 1999-12-16 | 2002-09-19 | Foster Todd P. | Pharmaceutical implant containing immediate-release and sustained-release components and method of administration |
| US6544553B1 (en) | 1999-12-28 | 2003-04-08 | Watson Pharmaceuticals, Inc. | Dosage forms and methods for oral delivery of progesterone |
| US20040022862A1 (en) | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
| FR2818905A1 (fr) | 2000-12-28 | 2002-07-05 | Cll Pharma | Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile |
| FR2821555B1 (fr) | 2001-03-01 | 2003-05-16 | Besins Int Lab | Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations |
| FR2832065B1 (fr) | 2001-11-13 | 2004-11-05 | Besins Int Belgique | Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations |
| EP1482946A1 (en) | 2002-03-14 | 2004-12-08 | Watson Pharmaceuticals, Inc. | Progesterone oral drug delivery system |
| US8216609B2 (en) | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| CN1231210C (zh) | 2002-08-20 | 2005-12-14 | 杭州容立医药科技有限公司 | 黄体酮胶囊组合物及其制备方法 |
| CN1678324A (zh) | 2002-08-28 | 2005-10-05 | 罗伯特·卡斯珀 | 雌激素替代治疗方案 |
| ES2338782T3 (es) | 2002-09-05 | 2010-05-12 | Pantarhei Bioscience B.V. | Composicion farmaceutica oral que comprende 15-hidroxitestosterona y derivados. |
| JP2004155780A (ja) | 2002-10-16 | 2004-06-03 | Taisho Pharmaceut Co Ltd | 生活習慣病改善剤組成物 |
| ATE482695T1 (de) | 2002-12-13 | 2010-10-15 | Durect Corp | Orale darreichungsform mit flüssigen hochviskosen trägersystemen |
| CN1282459C (zh) | 2002-12-24 | 2006-11-01 | 上海医药工业研究院 | 黄体酮胶丸及制备方法 |
| US20040266025A1 (en) * | 2003-02-06 | 2004-12-30 | Durlin Hickok | Screening and treatment methods for prevention of preterm delivery |
| GB0305941D0 (en) | 2003-03-14 | 2003-04-23 | Camurus Ab | Composition |
| CN1299686C (zh) | 2003-04-03 | 2007-02-14 | 上海医药工业研究院 | 黄体酮半固体骨架制剂的组合物 |
| CN1623550A (zh) * | 2003-12-04 | 2005-06-08 | 张伟 | 己酸羟孕酮口服制剂和用途 |
| CA2548281C (en) | 2003-12-09 | 2013-11-12 | Medcrystalforms, Llc | Method of preparation of mixed phase co-crystals with active agents |
| CN1933873A (zh) | 2004-03-19 | 2007-03-21 | 沃纳奇尔科特公司 | 延长周期的多相口服避孕方法 |
| GT200500186A (es) | 2004-07-07 | 2006-03-02 | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
| US7473687B2 (en) | 2005-03-24 | 2009-01-06 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
| US8663681B2 (en) | 2005-05-26 | 2014-03-04 | Teva Women's Health, Inc. | Oral dosage forms comprising progesterone and methods of making and using the same |
| US8828981B2 (en) * | 2007-02-06 | 2014-09-09 | George Creasy | Progesterone for the treatment or prevention of spontaneous preterm birth |
| SI2200588T1 (sl) | 2007-09-25 | 2019-08-30 | Solubest Ltd. | Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo |
| CA2744906A1 (en) | 2007-11-29 | 2009-06-04 | Gregg A. Jackson | Progesterone-containing compositions and devices |
| WO2010117873A2 (en) | 2009-04-06 | 2010-10-14 | Banner Pharmacaps, Inc. | Progesterone solutions for increased bioavailability |
| CA2779270A1 (en) | 2009-10-29 | 2011-05-05 | The Trustees Of The University Of Pennsylvania | Method of predicting risk of preterm birth |
| US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| US20110262502A1 (en) * | 2010-02-08 | 2011-10-27 | Prairie Pharmaceuticals LLC | Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc) |
| CA2789238C (en) | 2010-03-09 | 2020-05-12 | Dignity Health | Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening |
| US20110312928A1 (en) | 2010-06-18 | 2011-12-22 | Lipocine Inc. | Progesterone Containing Oral Dosage Forms and Related Methods |
| US20110312927A1 (en) | 2010-06-18 | 2011-12-22 | Satish Kumar Nachaegari | Progesterone Containing Oral Dosage Forms and Related Methods |
| US9375437B2 (en) | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| US8951996B2 (en) * | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
-
2016
- 2016-06-22 CN CN201680045227.5A patent/CN107847506A/zh active Pending
- 2016-06-22 MX MX2017016823A patent/MX2017016823A/es unknown
- 2016-06-22 ES ES16815246T patent/ES3005883T3/es active Active
- 2016-06-22 US US15/190,109 patent/US20170035781A1/en not_active Abandoned
- 2016-06-22 BR BR112017027688A patent/BR112017027688A2/pt not_active Application Discontinuation
- 2016-06-22 JP JP2017566077A patent/JP2018522854A/ja active Pending
- 2016-06-22 AU AU2016284459A patent/AU2016284459B2/en active Active
- 2016-06-22 WO PCT/US2016/038822 patent/WO2016210003A2/en not_active Ceased
- 2016-06-22 EP EP16815246.0A patent/EP3310359B1/en active Active
-
2017
- 2017-12-21 IL IL256493A patent/IL256493A/en unknown
- 2017-12-22 PH PH12017502416A patent/PH12017502416A1/en unknown
-
2018
- 2018-03-12 ZA ZA2018/01692A patent/ZA201801692B/en unknown
- 2018-08-06 US US16/055,594 patent/US20190275060A1/en not_active Abandoned
-
2020
- 2020-07-13 US US16/927,891 patent/US11590147B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210169900A1 (en) | 2021-06-10 |
| ES3005883T3 (en) | 2025-03-17 |
| WO2016210003A2 (en) | 2016-12-29 |
| PH12017502416A1 (en) | 2018-07-02 |
| US20170035781A1 (en) | 2017-02-09 |
| EP3310359A2 (en) | 2018-04-25 |
| US11590147B2 (en) | 2023-02-28 |
| BR112017027688A2 (pt) | 2018-09-04 |
| AU2016284459B2 (en) | 2021-12-23 |
| JP2018522854A (ja) | 2018-08-16 |
| US20190275060A1 (en) | 2019-09-12 |
| IL256493A (en) | 2018-02-28 |
| AU2016284459A1 (en) | 2018-02-15 |
| WO2016210003A3 (en) | 2017-02-09 |
| CN107847506A (zh) | 2018-03-27 |
| ZA201801692B (en) | 2019-09-25 |
| EP3310359B1 (en) | 2024-12-18 |
| EP3310359A4 (en) | 2019-04-03 |
| NZ739324A (en) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502416A1 (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
| MX385798B (es) | Composiciones orales que contienen un ester de 17-hidroxiprogesterona y metodos relacionados. | |
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| WO2013022783A3 (en) | Progesterone containing oral dosage forms and related methods | |
| WO2011160136A3 (en) | Progesterone containing oral dosage forms and related methods | |
| CY1124052T1 (el) | Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη | |
| CL2019000209A1 (es) | Formulación novedosa administrable por la vía oral. | |
| MY207496A (en) | Sustained-release formulations of colchicine and methods of using same | |
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
| CL2016001424A1 (es) | Composiciones de liberación retardada de lionaclotida | |
| NZ737948A (en) | Orodispersible dosage unit containing an estetrol component | |
| PH12013500173A1 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
| JP2018527305A5 (es) | ||
| EP2493312A4 (en) | Solid pharmaceutical compositions containing an integrase inhibitor | |
| RU2014142066A (ru) | Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения | |
| MX2014001065A (es) | Formulaciones de (trimetoxifenilamino) pirimidilino nuevas. | |
| IN2014MN02156A (es) | ||
| WO2016091805A3 (de) | Naloxon-monopräparat und mehrschichttablette | |
| MX2015010594A (es) | Esteres de testosterona de cadena larga lipobalanceados para suministro oral. | |
| RU2016136666A (ru) | Составы на основе прогестерона | |
| MX2017015699A (es) | Composiciones de acido diclofenaco. | |
| WO2020032883A3 (en) | Synergistic effects of a novel ketoprofen formulation including a gastro protective agent | |
| PH12019501607A1 (en) | Tapentadol nasal composition |